Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer

British Journal of Cancer

Volumn 88, Issue 3, 2003, Pages 335-341

  Negoro, S ^a   Masuda, N ^b   Takada, Y ^c   Sugiura, T ^d   Kudoh, S ^e   Katakami, N ^f   Ariyoshi, Y ^g   Ohashi, Y ^h   Niitani, H ⁱ   Fukuoka, M ^j  

^a OSAKA CITY GENERAL HOSPITAL   (Japan)

^b OSAKA PREFECTURAL MEDICAL CENTER FOR RESPIRATORY AND ALLERGIC DISEASES   (Japan)

^c HYOGO MEDICAL CENTER FOR ADULTS   (Japan)

^d AICHI CANCER CENTER HOSPITAL   (Japan)

^e OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f KOBE CITY MEDICAL CENTER GENERAL HOSPITAL   (Japan)

^g AICHI PREFECTURAL UNIVERSITY   (Japan)

^h UNIVERSITY OF TOKYO   (Japan)

ⁱ Tokyo Cooperative Oncology Group   (Japan)

^j KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Irinotecan; Non small cell lung cancer; Randomised phase III trial

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; IRINOTECAN;

ABDOMINAL PAIN; ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOTHESIS; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA; UREA NITROGEN BLOOD LEVEL; WEIGHT REDUCTION;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037428773     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600725     Document Type: Article

References (32)

1. Albain KS, Crowley JJ, LeBlanc M, Livingston RB (1991) Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. J Clin Oncol 9: 1618-1626
2. Baggstrom MQ, Socinski MA, Hensing TA, Poole C (2002) Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 21: 306a (abstract)
3. Belani CP, Natale RB, Lee JS, Socinski M, Robert F, Waterhouse D, Rowland K, Ansari R, Lilenbaum R, Sridhar K (1998) Randomized phase III trial comparing cisplatin/etoposide versus carboplatin/paclitaxel in advanced and metastatic non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 17: 455a (abstract)
4. Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinsky E, Jiroutek M, Johnson D (2000) Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J Clin Oncol 18: 623-631
5. Bunn Jr PA, Kelly K (1998) New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 4: 1087-1100
6. Cox DR, Oakes D (1984) Analysis of Survival Data. Chapman & Hall: London
7. Crino L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M (1999) Gemicitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 17: 3522-3530
8. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D, Hui S (1986) Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin C in advanced non-small-cell lung cancer. J Clin Oncol 4: 1037-1043
9. Espinosa E, Feliu J, Zamora P, González Barón M, Sánchez JJ, Ordóñez A, Espinosa J (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced non-small cell lung cancer. Lung Cancer 12: 67-76
10. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S, Taguchi T for the CPT-11 Lung Cancer Study Group (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
11. Giaccone G, Splinter TA, Debruyne C, Kho GS, Lianes P, van Zandwijk N, Pennucci MC, Scagliotti G, van Meerbeeck J, van Hoesel Q, Curran D, Sahmoud T, Postmus PE (1998) Randomized study of paclitaxel-cisplatin versus cisplatin-teniposide in patients with advanced non-small-cell lung cancer. The European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 16: 2133-2141
12. Johnson DH, Zhu J, Schiller J, Belani C, Langer CJ, Krook JE, Harrington D, Sandler AB (1999) A randomized phase III trial in metastatic non-small cell lung cancer-outcome of PS 2 patients (PTS): an Eastern Cooperative group trial (ECOG). Proc Am Soc Clin Oncol 18: 461a (abstract)
13. Kaplan EL, Meier P (1958) Nonparametric estimation for incomplete observations. J Am Stat Assoc 53: 457-481
14. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K (1991) Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 51: 4187-4191
15. Kubota K, Watanabe K, Kunitoh H, Noda K, Ichinose Y, Katakami N, Sugiura T, Kawahara M, Yokoyama A, Nishiwaki Y, Ohashi Y, Niitani H (2002) Final results of a randomized phase III trial of docetaxel and cisplatin versus vindesine and cisplatin in stage IV non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 21: 296a (abstract)
16. Kudoh S, Takada M, Masuda N, Nakagawa K, Itoh K, Kusunoki Y, Negoro S, Matsui K, Takifuji N, Morino H, Fukuoka M (1993) Enhanced antitumour efficacy of a combination of CPT-11, a new derivative of camptothecin, and cisplatin against human lung tumor xenografts. Jpn J Cancer Res 84: 203-207
17. Kurihara M, Shimizu H, Tsuboi K, Kobayashi K, Murakami M, Eguchi K, Shimozuma K (1999) Development of quality of life questionnaire in Japan: quality of life assessment of cancer patients receiving chemotherapy. Psychooncology 8: 355-363
18. Le Chevalier T, Brisgand D, Douillard JY, Pujol JL, Alberola V, Monnier A, Riviere A, Lianes P, Chomy P, Cigolari S (1994) Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients. J Clin Oncol 12: 360-367
19. Martoni A, Guaraldi M, Piana E, Strocchi E, Petralia A, Busutti L, Preti P, Robustelli G, Raimondi M, Ferrara G, Palomba G, Lelli G, Picece V, Recaldin E, Caffo O, Ambrosini G, Sarobba G, Farris A, Pannuti F (1998) Multicenter randomized clinical trial on high-dose epirubicin plus cis-platinum versus vinorelbine plus cis-platinum in advanced non small cell lung cancer. Lung Cancer 22: 31-38
20. Masuda N, Fukuoka M, Takada M, Kusunoki Y, Negoro S, Matsui K, Kudoh S, Takifuji N, Nakagawa K, Kishimoto S (1992) CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10: 1775-1780
21. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katakami N, Nakagawa K, Niitani H for the CPT-11 Lung Cancer Study Group (1998) A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group. Br J Cancer 78: 251-256
22. Mountain CF (1986) A new international staging system for lung cancer. Chest 89: 225S-233S
23. Negoro S, Fukuoka M, Masuda N, Takada M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, Niitani H, Taguchi T (1991) Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83: 1164-1168
24. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655
25. Paesmans M, Sculier JP, Libert P, Bureau G, Dabouis G, Thiriaux J, Michel J, Van Cutsem O, Sergysels R, Mommen P, Klastersky J for the European Lung Cancer Working Party (1995) Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1052 patients. J Clin Oncol 13: 1221-1230
26. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP (1988) Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer - report of a Canadian multicenter randomized trial. J Clin Oncol 6: 633-641
27. Ray P, Quantin X, Greníer J, Pujol J-L (1998) Predictive factors of tumor response and prognostic factors of survival during lung cancer chemotherapy. Cancer Detect Prev 22: 293-304
28. Schiller JH, Harrington D, Belani CP, Sandler A, Langer C, Sandler A, Krook J, Junming Z, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 346: 92-98
29. Schoenfeld DA, Richter JR (1982) Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics 38: 163-170
30. Statistics and Information Department, Minister's secretariat, Ministry of Health and Welfare (2000) Vital Statistics of Japan 1998 Table 2. Death by causes (The Condensed List of Causes of Death for Japan), Sex and Age, Vol 3. pp 384-397. Health and Welfare Statistics Association: Tokyo.
31. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48, World Health Organization: Geneva
32. Yana T, Takada M, Origasa H, Ijima T, Yamamoto N, Nakagawa K, Fukuoka M (2002) New chemotherapy agent plus platinum for advanced non-small cell lung cancer: a meta-analysis. Proc Am Soc Clin Oncol 21: 328a (abstract)